![Salah M. Abdel-Aleem](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Salah M. Abdel-Aleem
No más puestos en curso
Historial de carrera de Salah M. Abdel-Aleem
Antiguos cargos conocidos de Salah M. Abdel-Aleem.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Biopure Corp.
![]() Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Director Técnico/Científico/I+D | 17/11/2009 | - |
Corporate Officer/Principal | 01/08/2005 | 17/11/2009 |
Formación de Salah M. Abdel-Aleem.
City University of New York | Doctorate Degree |
Ain Shams University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 3 |
Egipto | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sectorial
Consumer Services | 3 |
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Biopure Corp.
![]() Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Salah M. Abdel-Aleem
- Experiencia